Genetic and Epigenetic Causes of Pituitary Adenomas

Mengqi Chang†, Chengxian Yang†, Xinjie Bao* and Renzhi Wang*

Department of Neurosurgery, China Pituitary Disease Registry Center, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

Pituitary adenomas (PAs) can be classified as non-secreting adenomas, somatotroph adenomas, corticotroph adenomas, lactotroph adenomas, and thyrotroph adenomas. Substantial advances have been made in our knowledge of the pathobiology of PAs. To obtain a comprehensive understanding of the molecular biological characteristics of different types of PAs, we reviewed the important advances that have been made involving genetic and epigenetic variation, comprising genetic mutations, chromosome number variations, DNA methylation, microRNA regulation, and transcription factor regulation. Classical tumor predisposition syndromes include multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) syndromes, Carney complex, and X-LAG syndromes. PAs have also been described in association with succinate dehydrogenase-related familial PA, neurofibromatosis type 1, and von Hippel–Lindau, DICER1, and Lynch syndromes. Patients with aryl hydrocarbon receptor-interacting protein (AIP) mutations often present with pituitary gigantism, either in familial or sporadic adenomas. In contrast, guanine nucleotide-binding protein G(s) subunit alpha (GNAS) and G protein-coupled receptor 101 (GPR101) mutations can lead to excess growth hormone. Moreover, the deubiquitinase gene USP8, USP48, and BRAF mutations are associated with adrenocorticotropic hormone production. In this review, we describe the genetic and epigenetic landscape of PAs and summarize novel insights into the regulation of pituitary tumorigenesis.

Keywords: pituitary adenomas, molecular markers, acromegaly, Cushing’s disease, non-secreting adenomas

INTRODUCTION

Pituitary adenomas (PAs) are the second most common brain tumors, accounting for approximately 15% of all primary brain tumors (1). PAs can be classified based on the types of hormones that they excessively secrete into the blood. The clinical presentations caused by hormone overproduction in PAs are closely related to the pituitary cell types, as follows: corticotropin-secreting corticotroph adenomas result in Cushing’s disease, growth hormone (GH)-secreting somatotroph adenomas result in acromegaly, prolactin-secreting lactotroph adenomas result in hyperprolactinemia, and thyrotropin-secreting thyrotroph adenomas result in hyperthyroidism (2). Non-secreting adenomas, such as null cell adenomas, silent gonadotroph adenomas, silent corticotroph adenomas, and silent somatotroph adenomas, lead to hypogonadism and often manifest as incidental sellar masses (2). Of the different PA types, only lactotroph adenomas are treated with dopamine agonists as
a first-line option. Because of a lack of effective drugs, other PA subtypes are generally treated with transsphenoidal surgery as the first-line therapy (3). Furthermore, because many PAs are invasive and unresectable—or in some cases of Cushing’s disease, because the tumors themselves are too small to be detected or completely removed during surgery—drugs and stereotactic radiosurgery are needed to achieve tumor control or biochemical remission. However, despite current treatments, the 10-year recurrence rate remains as high as 7–12% (3, 4). It is therefore important to obtain a comprehensive understanding of the molecular biological characteristics of different types of PAs, such as gene mutations, DNA methylation, microRNA (miRNA) regulation, and regulation at other levels, to allow the targeted treatment of individuals, thus achieving better prognoses. Herein, we summarize the known variation in the different types of PAs and review the potential molecular targets for future clinical application.

SYNDROMIC PITUITARY ADENOMA-RELATED VARIATIONS

Familial PAs can be divided into two types: isolated and syndromic (5). These familial PAs and their molecular mechanisms are described herein.

Multiple Endocrine Neoplasia Type 1 Syndrome

MEN1 syndrome is classically characterized by the combined occurrence of parathyroid adenomas, PAs (in approximately 30–40% of cases), and neuroendocrine tumors (6). PAs that develop in MEN1 syndrome include lactotroph adenomas (42–62%), silent PAs (15–42%), somatotroph adenomas (6.5–9%), and corticotroph adenomas (3–4%). In addition, somatic mutations in MEN1 can also be found in sporadic PAs (7). The MEN1 gene is located on chromosome 11q13.1 and encodes a ubiquitously expressed transcription cofactor of cyclins; MEN1 also participates in G1/S checkpoint regulation (8, 9). Approximately 10% of all MEN1-related PA cases can be attributed to de novo mutations, which are sometimes identified as a mosaicism in the proband (10, 11).

Multiple Endocrine Neoplasia Type 4 Syndrome

Some patients with MEN1 syndrome harbor no MEN1 mutation. Instead, cyclin-dependent kinase inhibitor 1B (CDKN1B) mutations have been detected in these patients. This syndrome is known as MEN4 syndrome (12). Patients with MEN4 syndrome are prone to developing somatotroph adenomas, and can also develop other types of PAs (13). CDKN1B mutations are rarely found in sporadic pituitary tumors (14, 15). CDKN1B encodes a cyclin-dependent kinase inhibitor that regulates the cell cycle and mitosis from the G1 to the S phase (13). CDKN1B-knockout mice develop various types of tumors, including PAs, and this tumorigenesis is associated with accelerated pituitary cell proliferation (16, 17). CDKN1B mutations likely lead to PAs by influencing cell cycle regulation.

Carney Complex

Carney complex is characterized by endocrine and non-endocrine tumors with spotty skin pigmentation, as well as by cardiac and cutaneous myxomas (18). More than two-thirds of patients present asymptomatic elevations of insulin-like growth factor 1 (IGF-1), GH, and prolactin caused by pituitary hyperplasia, and 10% of patients present with adrenomas and symptomatic acromegaly (19). In some cases, Carney complex is caused by an inactivating mutation of the PRKAR1A gene, which encodes the type 1-alpha regulatory subunit of protein kinase A (20). In addition, a gain-of-function mutation has been described in the gene encoding the catalytic subunit of protein kinase A, PRKACB (21).

X-LAG Syndrome

X-LAG syndrome is a newly defined syndrome in patients with pituitary gigantism or PA who carry microduplications on chromosome Xq26.3 (22, 23). X-LAG syndrome is generally recognized as an aggressive disease because it is difficult to control the excess GH. Most patients require multiple interventions (both surgical and medical), and subtotal or total hypophysectomy is sometimes necessary. In contrast, radiation therapy is not usually helpful. X-LAG syndrome is probably caused by G protein-coupled receptor 101 (GPR101) overexpression because the GPR101 gene is located on chromosome Xq26.3. GPR101 is coupled to the stimulatory G protein complex and activates adenylate cyclase, increasing cyclic adenosine monophosphate (cAMP) production. In addition, GPR101 amplification has also been identified as a germline mutation (22).

Succinate Dehydrogenase-Related Familial Pituitary Adenoma

This “3PAs” syndrome, which combines PA with pheochromocytoma/paraganglioma (PPGL), is sometimes associated with mutations in PPGL-predisposing genes, such as the genes encoding SDHx (24, 25). Such mutations occur in SDHA-D and SDHA2F, among others (24–28). SDH is a multimeric enzyme that binds to the inner membranes of mitochondria. It has a dual role: it serves both as a critical step of the tricarboxylic acid or Krebs cycle, and as a member of the respiratory chain that transfers electrons directly to the ubiquinone pool (25, 27, 29). Pituitary hyperplasia has been reported to develop in a Sdhb-knockout mouse model (25).

Neurofibromatosis Type 1 Syndrome

Rarely, optic pathway gliomas cause high GH levels in NF1, while true PAs are extremely rare. Empty sella syndrome and hypopituitarism may also occur in the context of NF1. Lifelong endocrine follow-up is recommended for all NF1 patients (13). A recent case report described a patient with a heterozygous guanine nucleotide-binding protein G(s) subunit alpha (GNAS) R201C mutation in a somatotroph adenoma. This was the first reported rare MEN1-like case of genetically diagnosed NF1 complicated with acromegaly caused by somatotroph adenoma (14).
Von Hippel–Lindau Syndrome

Von Hippel–Lindau syndrome is a heritable multisystem cancer syndrome that is caused by germline mutations of the VHL tumor suppressor gene. The incidence of this disorder is as high as 1 in 36,000 live births (15). Patients with VHL syndrome are at risk of developing various benign and malignant tumors of the central nervous system [i.e., pituitary stalk hemangioblastomas (15)], kidneys, adrenal glands, pancreas, and reproductive adnexal organs (16). It has been reported that propranolol can decrease the viability of VHL-related hemangioblastomas and renal cell carcinomas in vitro, likely by modulating vascular endothelial growth factor expression and inducing apoptosis (17). However, propranolol treatment for this disease is limited to early clinical trials.

DICER1 Syndrome

DICER1 syndrome is caused by heterozygous germline mutations in the DICER1 gene (30). Several cases have been reported of rare infantile-onset pituitary blastoma that were mainly caused by germline mutations in DICER1 (31). Recently, corticotroph adenomas have also been identified in this tumor syndrome (31). DICER1 encodes a cytoplasmic endoribonuclease that processes hairpin precursor miRNAs into short, functional miRNAs that downregulate targeted mRNAs, thereby modulating cellular protein production (32). In addition, specific somatic mutations in the DICER1 RNase III catalytic domain have been identified in several DICER1-associated tumor types (31, 33).

Lynch Syndrome

Lynch syndrome is a cancer-predisposing syndrome caused by germline mutations in genes involved in DNA mismatch repair (34). Germline mutations in MLH1 (35) and MSH2 (34) in the mismatch repair pathway, have been identified in Lynch syndrome patients with aggressive corticotropin-secreting adenomas, although these are isolated case reports. Missense mutations have also been detected in four mismatch repair genes (MSH5, MSH6, MLH1, and MLH3) in non-secreting adenomas (3).

Genetic Variations

Somatotroph adenomas have greater genomic disruption than corticotroph adenomas or inactive tumors with no clinical evidence of hormone secretion (38). Gene mutations in PAs can be divided into heritable germline variations, mosaic mutations, and non-heritable somatic mutations (29). The former two are often familial and associated with syndromes, while the latter are sporadic (29). Mutations in aryl hydrocarbon receptor-interacting protein (AIP), GNAS, and cadherin-related 23 (CDH23), which are all involved in cAMP-associated pathways, are key for somatotroph tumorigenesis (Figure 1, Table 1).

Aryl Hydrocarbon Receptor-Interacting Protein

Familial isolated pituitary adenoma (FIPA) is characterized by the familial occurrence of PAs in the absence of other clinical features (39). Germline mutations in the AIP gene are detected in approximately 20% of FIPA families and 50% of familial acromegaly families (40–43). AIP is located on human chromosome 11q13.2, and acts as a tumor suppressor in PAs (44). Mutations in AIP have been identified as causing a predisposition for PAs of variable penetrance in 20% of FIPA families (41). AIP mutations are usually associated with somatotropinomas, but prolactinomas, non-functioning PAs (NF-PAs), Cushing’s disease, and other infrequent clinical adenoma types can also occur (40–43). AIP mutations are common in male pediatric acrogigantism patients, and tend to cause large and invasive tumors; densely granulated subtypes rarely occur, and patients with AIP mutations are often resistant to somatostatin analogue (SSA) treatment (42, 43, 45, 46). Families with AIP mutations show incomplete penetrance, of approximately 15–30% (40, 42, 47). Genetic screening can identify carrier family members, and clinical screening has been reported to result in the earlier recognition of clinically relevant disease in approximately 20% of patients (22/187) (43).

Mechanically, some of the mutations lead to truncation of the AIP protein and loss of the C-terminal sequence, which affects protein interactions and leads to disrupted AIP function. A number of mechanisms may explain the resistance of AIP-mutated patients to SSAs. First, one mechanism may involve the reduced expression of the inhibitory G protein subtype, Gozi-2, which mediates the inhibitory effects of SSAs (44). Second, AIP has been reported to interact with both phosphodiesterase (PDE) and guanine nucleotide-binding proteins (G proteins); PDE4 expression is lower in AIP-mutated PAs, and interactions between PDE4 and AIP are disrupted by such mutations (44, 48, 49). Consistent with these findings, both PDE isoforms are reportedly overexpressed in GH cells from sporadic AIP mutation-negative GH-secreting adenomas (49). Third, AIP interacts with the protein kinase A (PKA) complex. AIP mutations affect the PKA pathway, thus affecting cell proliferation and development and the inflammatory response (42, 49). Fourth, another mechanism of SSA resistance may be related to the SSTR2–zinc-finger protein 1 PLAGL1 (ZAC1) pathway (50). AIP is upregulated by SSAs, and AIP can in turn

SOMATOTROPH ADENOMAS

The incidence of somatotroph adenomas is approximately 10 cases per 1 million individuals (2, 36, 37). Somatotroph adenomas are GH-secreting somatotropic tumors that exhibit excessive secretion of GH and IGF-1, causing acromegaly and abnormal growth of bones, tissues, and organs in patients. Currently, treatment methods are limited to surgery, radiotherapy, somatostatin receptor (SSTR) ligands, and GH receptor antagonists. Each of these treatments has specific side effects, and the efficacy varies greatly among different patients; thus, it is hard to directly target and inhibit the continuous secretion of GH in postoperative patients (2). It is necessary to further understand the molecular mechanisms of somatotroph adenomas to elucidate new therapeutic targets.
FIGURE 1 | Tumorigenic mechanisms in somatotroph cells. Several mechanisms increase cAMP production, which is key for somatotroph tumorigenesis. Hormones bind to receptors, including GHRH-R, SSTR, GPR101, and GIPR, on the somatotroph cell membrane and increase the activation of adenylyl cyclase through Gsα. The consequent increase in cAMP production leads to the dissociation of the regulatory subunits of PKA from the catalytic subunits, which then translocate to phosphorylate CREB in the nucleus and other targets, leading to increased GH expression and cell proliferation. Gsα activation induced by GNAS mutations also leads to upregulation of the cAMP pathway. In addition, ectopic expression of GIPR may lead to an activated cAMP pathway, and GPR101 is a Gsα-coupled constitutively active receptor that leads to increased cAMP signaling. AIP, aryl hydrocarbon receptor-interacting protein; ATP, adenosine triphosphate; C, catalytic subunit; cAMP, cyclic adenosine monophosphate; CREB, cAMP response element; GHRH, growth hormone-releasing hormone; GHRH-R, GHRH receptor; GIPR, gastric inhibitory polypeptide receptor; GPR101, G protein-coupled receptor 101; Gsα, G protein stimulatory alpha subunit; GTP, guanine triphosphate; PKA, protein kinase A; R, regulatory subunit; SSTR, somatostatin receptor; ZAC1, zinc finger protein PLAGL1.

TABLE 1 | Genes affected in different pituitary tumors via genetic mutation or DNA methylation.

| Gene (symbol) | Gene name | Location | Function of gene product and mechanism of tumorigenesis | Tumor types associated with each genetic defect |
|-------------|------------|----------|--------------------------------------------------------|-----------------------------------------------|
| MEN1        | Multiple Endocrine Neoplasia type 1 | 11q13.1 | Tumor suppressor; Involved in cell proliferation, genome stability and gene transcription | Lactotroph adenomas, somatotroph adenomas, corticotroph adenomas, and nonsecreting adenomas |
| CDKN1B      | cyclin-dependent kinase inhibitor 1B | 12p13.1 | Cell cycle regulation | Prone to developing somatotroph adenomas, and can also develop other types of PAs |
| PRKAR1A      | Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha | 17q24.2 | Loss of PRKAR1A causes enhanced PKA signaling. | Somatotroph adenomas and lactotroph adenomas |
| GPR101       | G-protein-coupled receptor gene | Xq26.3 | G-protein-coupled receptor; defects lead to constitutive activation of the cAMP-PKA pathway | Somatotroph adenomas |
| SDHx         | Succinate dehydrogenase x | / | Unknown | More likely to produce prolactin; pituitary hyperplasia in mice |
| VHL          | Von Hippel–Lindau | 3p25.3 | Likely by modulating vascular endothelial growth factor expression and inducing apoptosis | Pituitary stalk hemangioblastomas |
| DICER        | Dicer 1, Ribonuclease III | 14q32 | Unknown | Pituitary blastoma |
| MLH1         | MutL Homolog 1 | 3p22.2 | Unknown | Corticotroph adenomas |
| MSH2         | MutS Homolog 2 | 2p21 | Unknown | Corticotroph adenomas |
| AIP          | Aryl hydrocarbon receptor interacting protein | 11q13.2 | Interaction in cAMP synthesis | All types |

(Continued)
| Gene (symbol) | Gene name | Location | Function of gene product and mechanism of tumorigenesis | Tumor types associated with each genetic defect |
|--------------|-----------|----------|--------------------------------------------------------|-------------------------------------------------|
| GNAS         | Guanine nucleotide activating subunit | 20q13.32 | cAMP-regulating protein Gsα; activation leads to increased cAMP levels and activation of protein kinase A (PKA) | Mainly in somatotroph adenomas |
| PTTG1        | Pituitary tumor-transforming gene-1 | 5q33.3 | Enhanced PTTG1 is a regulator of sister chromatid segregation, this may subsequently drive chromosomal instability | All types |
| STAT3        | Signal Transducer and Activator of Transcription 3 | 17q21.2 | Increased STAT3 increased GH transcription. | Somatotroph adenomas |
| CDH23        | Cadherin related 23 | 10q22.1 | Calcium-dependent cell-cell adhesion glycoprotein | Somatotroph adenomas account for the highest proportion |
| IGSF1        | Immunoglobulin superfamily member 1 | Xq26.1 | IGSF1 mutation weakens its transport to the cell surface in allogenic cells and increased total GH secretion and IGF-1 levels | Hyperplasia with increased total GH secretion and IGF-1 levels |
| SLC20A1      | Solute Carrier Family 20 Member 1 | 2q14.1 | Increased expression of SLC20A1 may be associated with the activation of the Wnt/β-catenin signaling pathway | Somatotroph adenomas |
| PRDM2        | PR/SET Domain 2 | 1p36.21 | The absence of PRDM2 involved the tumorigenesis through regulating c-Myc | Somatotroph adenomas |
| SSTRs and DRDs | Somatostatin receptors (SSTR1-5) and dopamine receptors (DRD1-5) | / | Decreased expression of receptors (DRD4, DRD5, SSTR1 and SSTR2) may be associated with poor response to SSAs | Somatotroph adenomas and silent somatotroph adenomas |
| IGSF1        | Immunoglobulin Superfamily Member 1 | Xq26.2 | Membrane glycoprotein with modified residue possibly altering interaction with an extracellular ligand | Hyperplasia, and sometimes with GH secretion and IGF-1 level increasing |
| SLC20A1      | Solute Carrier Family 20 Member 1 | 2q14.1 | Increased SLC20A1 expression may be associated with activation of the Wnt-β-catenin signaling pathway | Somatotroph adenomas |
| PRDM2        | PR domain zinc finger protein 2 | 1p36.21 | c-Myc regulation | Somatotroph adenomas |
| GADD45γ      | Growth Arrest and DNA Damage Inducible Gamma | 9q22.2 | Tumor suppressor; Involved in DNA damage and function in the negative regulation of cell growth | Non-secreting adenomas and somatotroph adenomas |
| LGALS3       | Galectin 3 | 14q22.3 | Promoter methylation status of LGALS3 for the regulation of Gal-3 expression in PA | Lactotroph adenomas, corticotroph adenomas |
| RASSF1A      | Ras Association Domain Family Member 1 | 3p21.31 | Promoter methylation of RASSF1A is detected in all types of PAs and mechanism is unknown, | All types |
| USP8         | Ubiquitin Specific Peptidase 8 | 15q21.2 | Involved in deubiquitination of EGFR; gain of functions mutations results in increased EGFR, and POMC expression | Corticotroph adenomas |
| USP48        | Ubiquitin Specific Peptidase 48 | 1p36.12 | Deubiquitination; activation of MAPK and increased POMC expression | Corticotroph adenomas |
| BRAF         | B-Raf Proto-Oncogene, Serine/Threonine Kinase | 7q34 | Proto-oncogene with tyrosine kinase activity; activation of MAPK and increased POMC expression | Corticotroph adenomas |
| USP90        | Heat Shock Protein 90 | / | Unknown | Corticotroph adenomas |
| HDAC2        | histone deacetylase 2 | 6q21 | Unknown | Corticotroph adenomas |
| CABLES1      | Cdk5 And Abl Enzyme Substrate 1 | 18q11 | Unknown | Corticotroph adenomas |
| SFRP2        | Secreted Frizzled-Related Protein 2 | 4q31.3 | overexpression of SFRP2 in AtT20 cells reduces β-catenin levels in the cytoplasm and nucleus, and also decreases Wnt signaling activity | Corticotroph adenomas |
| POMC         | Proopiomelanocortin | 2p23.3 | Unknown | Corticotroph adenomas |
| FGFR2        | Fibroblast Growth Factor Receptor 2 | 10q26.13 | Inducing Rb phosphorylation and regulation of cell cycle progression by p21 and p27 | Corticotroph adenomas |
| PTAG         | Pituitary Tumor Apoposis Gene | 22q12.2 | Unknown | Corticotroph adenomas |
| TSP-1        | Thrombospondin-1 | 15q14 | Unknown | Corticotroph adenomas |
| CASP-8       | Caspase-8 | 2q33.1 | Unknown | Corticotroph adenomas |
| CABLES1      | Cdk5 And Abl Enzyme Substrate 1 | 18q11 | Unknown | Corticotroph adenomas |
| CSorf66-AS1  | CSorf66 Antisense RNA 1 | 5q31.1 | Unknown | Pituitary null cell adenomas |
| IL-6R, JAK2, STAT3, p-STAT3, and MMP9 | Oncogene; Involved in PI3K/AKT pathway which regulates several cellular functions, including cell survival, growth, proliferation, and metabolism | / | Unknown | Pituitary null cell adenomas |
| PI3K         | Phosphatidylinositol 3-kinases | 3p26.32 | Oncogene; Involved in PI3K/AKT pathway which regulates several cellular functions, including cell survival, growth, proliferation, and metabolism | Non-secreting adenomas |
| CDKN2A       | Cyclin dependent Kinase Inhibitor 2A | 9p21 | Tumor suppressor; Cell cycle regulation (G1 to S phase transition) | Non-secreting adenomas and somatotroph adenomas |

(Continued)
upregulate ZAC1 mRNA expression (51, 52). Disordered cAMP regulation is important for the resistance of AIP mutations to SSA treatment (42, 49).

**Guanine Nucleotide-Binding Protein G(s) Subunit Alpha**

GNAS encodes the stimulatory α subunit of the G protein complex, which plays an important role in transmembrane signal transduction (53). Its mutation rate is the highest of somatic mutations in somatotroph adenomas (up to 40%). GNAS-mutated tumors are often smaller and less invasive, respond better to SSAs, and are usually densely granulated somatotroph adenomas (52, 54, 55). In addition, GNAS-mutated tumors have relatively high expression of dopamine receptor (DRD) 2, which suggests a good response to dopamine agonists (38). Somatic mutations in GNAS can result in sporadic somatotroph adenomas, while mosaic mutations for codon 201 likely result in McCune–Albright syndrome. This syndrome is characterized by polyostotic fibrous dysplasia, skin hyperpigmentation, and autonomous endocrine hyperfunction (56).

GNAS mutations can also lead to disruption of the cAMP signaling pathway. Especially, mutations in codon 201 or 227 result in the inhibition of G proteins and the activation of adenyl cyclase, promote cAMP synthesis in cells, and drive tumorigenesis (57). Recently, a GNAS mutation (p.Arg201Cys) has been detected as a recurrent somatic event, and this mutation is shared with chromosome losses (58, 59).

**Copy Number Variations at the Chromosomal Level**

Recent studies have indicated that increased cAMP in tumorigenesis can probably induce DNA damage, leading to somatic CNVs and genome instability (60). Of these, arm-level CNVs are the most common abnormalities in somatotroph adenomas. Specifically, whole chromosome losses (chromosomes 1, 6, 13, 14, 15, 16, 18, and 22) and gains (chromosomes 3, 5, 7, 10, 19, 20, and X) have been observed (58, 59, 61). Interestingly, GNAS mutation-positive adenomas have relatively low CNV levels, whereas GNAS mutation-negative adenomas have a high degree of genomic disruption (58, 59, 61). These CNVs likely affect the Ca^{2+} and ATP pathways, which are involved in PA tumorigenesis (58, 59, 61). Thus, the CNVs in GNAS mutation-negative somatotroph adenomas provide an alternative tumorigenic pathway, which is linked to genomic instability (58, 59, 61).

**Less Common Genetic Variations Potentially Associated With Pituitary Adenomas**

Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in various pituitary tumors, and its expression is higher in more aggressive tumors (62–64). Somatotroph adenomas with recurrent aneuploidy have relatively high expression of PTTG1; as a regulator of sister chromatid segregation, this may subsequently drive chromosomal instability (64–66).

**Signal Transducer and Activator of Transcription 3**

STAT3 is a member of the STAT family, and participates in cellular responses to cytokines and growth factors (67). Its expression is enhanced in somatotroph adenomas, leading to GH hypersecretion, which in turn promotes STAT3 expression (68). In primary human somatotroph adenoma-derived cell cultures, the specific inhibitor S3I-201 can inhibit STAT3 expression, thus decreasing GH transcription and reducing GH secretion (68).

**CDH23**

CDH23 is involved in Wnt pathway regulation. The CDH23 c.4136G>T (p.Arg1379Leu) mutation leads to an amino acid substitution in the calcium-binding motif of the extracellular cadherin domain, which is predicted to disrupt cell–cell adhesion. The incidence rate of CDH23 mutations is 33% in FIPA patients and 12% in sporadic PA patients. Of the CDH23-mutated PAs, somatotroph adenomas account for the highest proportion (25.9%) (69). PAs with functional CDH23 variants are smaller and less aggressive compared with non-mutated PAs (69, 70). In addition, variants in this gene are associated with Usher syndrome (70). However, CDH23 variations have been reported in only one study, and functional validation studies are needed.

**Immunoglobulin Superfamily Member 1**

IGSF1 is a membrane glycoprotein. IGSF1 mutations can weaken its transport to the cell surface in allogenic cells, resulting in a novel X-related syndrome. This syndrome is characterized by central hypothyroidism, macro-orchidism, and prolactin deficiency (71–73). It can also be associated with acromegaloïd facial features, increased head circumference, and increased total GH secretion and IGF-1 levels. However, considering that patients present with hyperplasia rather than adenomas, these
symptoms may be secondary to the failure of regulatory and feedback mechanisms.

**Solute Carrier Family 20 Member 1**

SLC20A1 levels are positively associated with tumor size, invasive behavior, and recurrence in somatotroph adenomas. In addition, increased SLC20A1 expression may be associated with activation of the Wnt–β–catenin signaling pathway (74).

**PR Domain Zinc Finger Protein 2**

PRDM2, a tumor suppressor, plays an important role in cancer and obesity, including PAs. The absence of PRDM2 is likely to be involved in the tumorigenesis of somatotroph adenomas by regulating c-Myc (75). However, this discovery remains to be validated by more investigation groups.

**Somatostatin Receptors and Dopamine Receptors**

SSTR (SSTR1–5) and DRD (DRD1–5) subtypes play critical roles in the regulation of hormone secretion (76). Decreased expression of some of these receptors (DRD4, DRD5, SSTR1, and SSTR2) may be associated with a poor response to SSAs (77). In particular, SSTR2 expression might be a good predictor of a patient’s response to SSAs (78).

**DNA Methylation**

DNA methylation is the most frequently studied epigenetic phenomenon, in which alterations of CpG dinucleotides block the transcriptional mechanism and silence gene expression (79). Approximately 80% of CpG dinucleotides are methylated in the human genome throughout the lifespan, and nearly 70% of CpG islands are methylated at any time, suggesting a widespread regulatory scope of DNA methylation (80). Here, we summarize the methylated genes in somatotroph adenomas (Table 1).

Growth arrest and DNA damage-inducible gene (GADD45γ) is a negative regulator of cell growth that is involved in DNA damage repair. In one study, most PAs (22/33, 67%) did not have GADD45γ expression, and 57.6% (19/33) of PAs were detected with GADD45γ methylation; there was significantly associated between GADD45γ methylated tumors and tumors in which GADD45γ transcript was not expressed (18 of 22; 82%; P = 0.002) (81). The silencing of GADD45γ is likely to confer a selective growth advantage during PA tumorigenesis (82).

The importance of the promoter methylation status of LGALS3 (the gene encoding galectin-3) for the regulation of galectin-3 expression in PA was confirmed by Ruebel et al. Ikaros, a factor with transcriptional functions and chromatin-remodeling properties that determine the fate of hypothalamic neuroendocrine and pituitary cell populations during development, may also contribute to the expression of galectin-3 (83).

The human Ras-association domain family 1A (RASSF1A) gene has been reported as frequently (38%, 20/52) hypermethylated in its promoter region in all types of PAs. RASSF1A promoter methylation is relatively low in gonadotroph cell adenomas, higher in the most aggressive adenomas, and potentially correlated with Ki-67 expression. Reduced expression of RASSF1A has been identified in 18 of 20 (90%) adenomas with hypermethylation of RASSF1A (84).

**miRNA Regulation**

miRNA binding to the 3’ and 5’ untranslated regions and coding sequences of target RNA is a form of post-transcriptional modification that results in differential gene expression. miRNAs play an important role in various pathways in tumors.

**High-Mobility Group AT-Hook 1/2 Regulation**

Palumbo et al (85). reported that miRNAs that target HMGA, including miR-15, miR-16, miR-26a, let-7a, miR-196a2, and other miRNAs, are downregulated in PAs. These HMGA-targeting miRNAs have also been demonstrated to inhibit the proliferation of a somatotroph adenoma cell line (GH3) and promote pituitary tumorigenesis. Furthermore, D'Angelo et al. reported that downregulated miRNAs, including miR-326, miR-570, and miR-432, target HMGA1 and HMGA2; while miR-34b and miR-548c-3p target HMGA2; and miR-603 and miR-326 target E2F transcription factor 1 (E2F1). In addition, some miRNAs are downregulated in somatotroph adenomas, including miR-34b, miR-326, miR-432, miR-548c-3p, miR-570, and miR-603 (86). The long non-coding RNA (lncRNA) ribosomal protein SA pseudogene 52 (RP5AP52) is overexpressed in PAs. It promotes cell proliferation in a competing endogenous RNA (ceRNA)-dependent manner by competitively binding to miR-15a, miR-15b, and miR-16, and by upregulating the expression of HMGA1 and HMGA2 (87, 88).

**Phosphatase and Tensin Homolog – Protein Kinase B Pathway**

Downregulated and upregulated miRNAs sometimes work together. For example, the downregulation of miR-26b expression together with the upregulation of miR-128 suppresses colony formation ability and invasiveness, and regulates the activity of the PTEN–AKT pathway in somatotroph adenomas (85).

**PTTG1 Regulation**

Multiple miRNAs are associated with the increased expression of PTTG1. First, miR-338-3p is upregulated in invasive somatotroph adenomas, and probably mediates the increased expression of PTTG1 (89). Second, miR-423-5p, which targets PTTG1, shows decreased expression in somatotroph adenomas, and inhibits the expression of PTTG1 at both the mRNA and protein levels (90). Third, overexpression of miR-524-5p downregulates the expression of PTTG1-binding factor, which interacts with PTTG1 to mediate downstream effects, and significantly attenuates proliferation, migration, and invasion in vitro (91).

**CORTICOTROPIN-SECRETING ADENOMAS**

Corticotropin-secreting adenomas account for 15% of PAs, with an incidence of 1.6 cases per 1 million individuals. These adenomas are typically small, and the excessive secretion of corticotropin leads to adrenal hypercortisolism (92). Although 75% of patients achieve remission after surgical treatment, recurrence occurs in approximately 10% of these patients (93).
Current pituitary-targeted drugs, including cabergoline and pasireotide, can improve the clinical features of excessive hormone secretion, but 60–75% of patients are insensitive to these drugs, which cannot control the symptoms long after drug treatment (94). Therefore, an understanding of the molecular characteristics of these tumors is necessary to identify additional drug targets. Here, we summarize the abnormal alterations in corticotropin-secreting adenomas that may serve as potential therapeutic targets (Figure 2, Table 1).

**Genetic Variations**

**Ubiquitin-Specific Peptidase 8**

*USP8* encodes a deubiquitinase enzyme that protects epidermal growth factor receptor (EGFR) from degradation. Up to 62.4% of corticotropin-secreting adenomas were found to have *USP8* mutations that block 14-3-3 protein binding, leading to increased activity of USP8 (95–97). Gain-of-function mutations in *USP8* increase the deubiquitination of EGFR, which inhibits its degradation, leading to the activation of EGFR signaling. This mechanism likely leads to the synthesis and secretion of adrenocorticotropic hormone (ACTH) and promotes tumorigenesis (95–98). In *USP8*-mutated corticotropin-secreting adenoma samples, the cell cycle inhibitor p27, heat shock protein 90 (HSP90), and phosphorylated cAMP-response element binding protein (pCREB) were significantly reduced, suggesting that these proteins are direct or indirect clients of *USP8* and could therefore be potential targets for treatment (99).

*USP8* mutations have also been identified in silent corticotroph adenomas (100). Transcriptomic profiles show significant differences between functioning and silent corticotroph adenomas. However, *USP8* mutations have pleiotropic effects in both functioning and silent corticotroph adenomas, and affect the expression levels of many genes that are involved in a range of different pathways (100).

Germline *USP8* mutations, which are commonly found as somatic mutations in corticotropin-secreting adenomas, have also recently been described in a child with dysmorphic features, developmental delay, and a corticotroph adenoma (101). In addition, an overall prevalence of *USP8* mutations of 32% has been reported in corticotropin-secreting adenomas. *USP8*-mutated tumors are more common in females, and are associated with earlier onset (96, 102), a smaller size (95), and increased ACTH production (95, 102). Patients with *USP8*-mutated tumors are more likely to go into initial remission after surgery, but may also be more likely to show recurrence later in the clinical course (102–104). In contrast, *USP8*-mutation-negative tumors are more likely to show sphenoid invasion with an increased epithelial–mesenchymal transition signature (38). Lapatinib, an EGFR inhibitor, decreases proliferation *in vitro* and reduces tumor weight *in vivo* (105). In addition, SSTR5 expression is higher in *USP8*-mutated tumors.

**Figure 2** Tumorigenic mechanisms in corticotroph cells. *USP8* removes ubiquitin tags from targets, such as EGFR and Smoothened (SMO), preventing them from undergoing proteasomal degradation and allowing recycling back to the cell surface. Increased EGFR and SMO activity leads to increased cAMP and POMC levels. Mutated *USP8* cannot bind 14-3-3 protein and undergoes cleavage, which increase enzymatic activity, leading to increased deubiquitination of EGFR and SMO and higher expression of the two proteins on the cell membrane. *USP48* mutations and gain-of-function mutations of *BRAF* probably play a similar role to *USP8*. 

![Figure 2](https://example.com/figure2.png)
and dog corticotropin-secreting adenomas, which are the hallmark previously shown that approximately 50% of Gc-resistant human HDAC2 should therefore produce Gc resistance, and we have resistance, Brg1 and HDAC2 de these proteins. In addition to providing a molecular basis for Gc feature of the hypothalamo--pituitary--adrenal axis. Loss of Brg1 or HDAC2 should therefore produce Gc resistance, and we have previously shown that approximately 50% of Gc-resistant human and dog corticotropin-secreting adenomas, which are the hallmark of Cushing’s disease, have deficient nuclear expression of either of these proteins. In addition to providing a molecular basis for Gc resistance, Brg1 and HDAC2 deficiencies may also contribute to the tumorigenic process (111).

**USP48 and BRAF**

With the recognition of the importance of USP8 mutations, another two mutated genes in the mitogen-activated protein kinase (MAPK) pathway, USP48 and BRAF, have also been detected in corticotropin-secreting adenomas (108). Missense mutations in USP48 include M4151/V substitutions, while V60OE is an activation mutation of BRAF. Among tumors without USP8 mutations, 23% of corticotropin-secreting adenomas have USP48 mutations and 16% have BRAF mutations (108). Both mutations enhance the promoter activity and transcription of the ACTH precursor, the proopiomelanocortin (POMC) gene, and are potential therapeutic targets for the excess secretion of ACTH in corticotropin-secreting adenomas. Furthermore, USP48 variants are associated with smaller tumors and a better response to corticotropin-releasing hormone (CRH) stimulation (109). Therefore, variations in EGFR regulation, the MAPK pathway, and POMC-related genes play a certain role in corticotropin-secreting adenomas.

**Less Common Genetic Variations Potentially Associated With Pituitary Adenomas**

**Heat Shock Protein 90 (HSP90)**

Corticotroph adenomas overexpress HSP90 compared with the normal pituitary gland. N- and C-terminal HSP90 inhibitors act at different stages of the HSP90 catalytic cycle to regulate corticotropic cell proliferation and glucocorticoid (Gc) receptor (GR) transcriptional activity. The C-terminal HSP90 inhibitor silibinin has been reported to have anti-tumorigenic effects, partially decrease hormonal secretions, and alleviate the symptoms of Cushing’s disease in a mouse model (110).

**Brg1 and Histone Deacetylase 2**

The negative feedback regulation of POMC by GRs is a critical feature of the hypothalamo--pituitary--adrenal axis. Loss of Brg1 or HDAC2 should therefore produce Gc resistance, and we have previously shown that approximately 50% of Gc-resistant human and dog corticotropin-secreting adenomas, which are the hallmark of Cushing’s disease, have deficient nuclear expression of either of these proteins. In addition to providing a molecular basis for Gc resistance, Brg1 and HDAC2 deficiencies may also contribute to the tumorigenic process (111).

**CDK5 and ABL1 Enzyme Substrate 1**

CABLES1 is a cell cycle regulator that participates in the adrenal--pituitary negative feedback loop. Four heterozygous germline missense variants have been identified in CABLES1 in four sporadic patients from a cohort of 182 patients with corticotropin-secreting adenomas, with functional evidence. The four variants affected residues within or close to the predicted cyclin-dependent kinase-3 (CDK3)-binding region of the CABLES1 protein and impaired its ability to block cell growth in a mouse corticotropinoma cell line (AtT20/D16v-F2). However, further studies are needed to assess the prevalence of CABLES1 mutations in patients with other types of PAs, and to elucidate the pituitary-specific functions of this gene (111).

**Secreted Frizzled–Related Protein 2 (SFRP2)**

The RNA and protein expression of SFRP2 is decreased in corticotroph adenomas compared with normal pituitary glands (112). In addition, the overexpression of SFRP2 in AtT20 cells reduces β-catenin levels in the cytoplasm and nucleus, and also decreases Wnt signaling activity. SFRP2 may therefore act as a tumor suppressor in Cushing’s disease by regulating Wnt signaling pathway activity. Clinically, there is an association between lower SFRP2 expression and aggressive adenoma characteristics, including a larger size and invasiveness (112).

**DNA Methylation**

Although some corticotropin-secreting adenomas have been found to have genetic mutations, the pathogenesis of non-mutated adenomas remains unknown. DNA methylation, a complementary mechanism for gene mutations, also plays an important role in PAs.

**POMC**

Hypomethylation of the promoter of POMC, which encodes the precursor of ACTH, leads to the occurrence of corticotropin-secreting adenomas. A comparison of the methylation profiles of ACTH-PAs and NF-PAs showed that the overexpression of POMC likely accounts for promoter hypomethylation (3). As a pituitary hormone, ACTH leads to increased serum cortisol levels in patients with Cushing’s disease, which is associated with the occurrence of corticotropin-secreting adenomas.

**Fibroblast Growth Factor 2**

FGF2 is a potent growth factor that regulates stem cell maintenance and neurogenesis during embryonic development and in response to challenges such as stress or injury in the adult brain (113–117). FGFR2 encodes a growth factor receptor, and was found to be methylated by a 5’ promoter in mouse AtT20 cells, leading to significantly downregulated expression (80).

**Pituitary Tumor Apoptosis Gene**

In a model pituitary tumor cell line (AtT20), enforced expression of PTAG is associated with significantly increased sensitivity to the apoptotic effects induced by bromocriptine challenge (118).

**Thrombospondin-1**

The secreted angioinhibitory factor TSP-1 is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions, and is associated with platelet aggregation, angiogenesis, and tumorigenesis. Overexpression of TSP-1 in a murine AtT20 pituitary corticotroph tumor cell line leads to increased ACTH secretion (119).

**ESR1 and Caspase 8**

The methylation levels of ESR1 and CASP8 in corticotropin-secreting adenomas are also increased compared with those of silent corticotroph adenomas. CASP8 plays an important role in apoptosis. Furthermore, CASP8 has been suggested to affect the
functional behavior of corticotroph adenomas, but the specific mechanisms remain unknown. The methylation of POMC, FGFR2, RASSF1A, LGALS3, and apoptosis-related factors plays a potential role in the development of corticotropin-secreting adenomas.

**MiRNA Regulation**

The tumor suppressors miR-15a, miR-16, and miR-132 are downregulated in corticotroph adenomas. These miRNAs inhibit the proliferation, invasion, and migration of pituitary tumor cells by targeting sex-determining region Y-box 5 (SOX5) (120). In addition, the following miRNAs are also reportedly downregulated in corticotroph adenomas: miR-145 (2.0 fold), miR-21 (2.4 fold), miR-141 (2.6 fold), let-7a (3.3 fold), miR-150 (3.8 fold), and miR-143 (6.4 fold), suggesting that they may play a role in the tumorigenesis of corticotropin-secreting adenomas. miR-26a is overexpressed in corticotroph adenomas, and one of its direct targets is protein kinase Cε (PRKCD) (85). PRKCD silencing is associated with increased EGFR expression, indicating PRKCD as a possible molecular target for the treatment of corticotroph adenomas (121, 122).

**NON-SECRETING ADENOMAS**

Non-secreting adenomas account for 20–35% of PAs originating from different hormone-secreting cells. Many of these are gonadotroph adenomas, and some show somatotroph, corticotroph, thyrotroph, or lactotroph differentiation. In older studies, the diagnosis of non-functional adenomas was mainly based on the normal results of hormone secretion rather than the results of immunohistochemical staining. However, with recently updated pituitary tumor classifications, the diagnosis of non-functional adenomas is made according to detailed pituitary cell types. Because excessive hormone levels are not found in the blood with non-secreting adenomas, they may not be detected for years in patients, and are often diagnosed incidentally (92). Although mostly benign, some invasive pituitary tumors require adjuvant radiation after surgery, often resulting in pituitary failure and a risk of recurrence. In an effort to aid in the development of additional treatment methods, we herein summarize the molecular signatures of non-secreting adenomas (Table 1).

**Genetic Variations in Null Cell Adenomas**

**C5orf66-AS1**

C5orf66-AS1 encodes a lncRNA that is differentially expressed between pituitary null cell adenoma tissues and normal pituitary tissues, as well as between invasive and non-invasive tumors (123). Co-expression analysis in RNA sequencing data revealed that PAQR7 [a membrane progesterone receptor that may mediate a reduction in gonadotropin-releasing hormone in the progesterone negative feedback action in a progesterone receptor (A/B)-independent way (124)] was the gene that was most correlated with C5orf66-AS1, and several predicted trans-acting target genes, including SCGB3A1 (encoding secretoglobin family 3A member 1), were also highly correlated with C5orf66-AS1 (123). These results indicate that C5orf66-AS1 suppresses the development and invasion of pituitary null cell adenomas (123).

**Interleukin 6 Receptor (IL-6R)/Janus Kinase 2 (JAK2)/STAT3/Matrix Metallopeptidase 9**

Integrative proteomics and transcriptomics have revealed the activation of IL6R, JAK2, and STAT3, and the overexpression of IL-6R, JAK2, STAT3, p-STAT3, and MMP9, in invasive pituitary null cell adenomas (125). Therefore, activation of the IL-6R–JAK2–STAT3–MMP9 signaling pathway is correlated with the invasiveness of pituitary null cell adenomas.

**Genetic Variations in Silent Somatotroph Adenomas**

**Somatostatin Receptor 2 and Dopamine Receptor 2**

There is a negative correlation between SSTR2 and tumor size in silent somatotroph adenomas. Additionally, levels of DRD2 expression are reportedly similar between silent and functioning somatotroph adenomas, suggesting a possible basis for the treatment of these tumors with SSAs and dopamine (126).

**Genetic Variations in Non-Secreting Tumors Without Classification**

**Phosphatidylinositol 3-Kinases**

PI3K is an important regulator of cell growth, transformation, adhesion, apoptosis, survival, and movement. The catalytic subunit encoding the PIK3CA gene is located on chromosome 3q26.3 and is often found to be deficient in cancer (127). Somatic mutations have been detected in 8 out of 91 (9%) of invasive pituitary tumors versus 0 out of 262 (0%) non-invasive tumors (128). In addition to mutations of PI3K, mutations of MEN1, AIP (129), and CDH23 (69) have also been detected in non-secreting adenomas. In this section, we summarize the gene mutations in cell cycle regulators, phosphokinase, the cAMP signaling pathway, and cadherin that are associated with the occurrence of non-secreting adenomas.

**DNA Methylation**

The p16 protein, encoded by the tumor suppressor gene CDKN2A, is located on chromosome 9p21. CDKN2A has been found to exhibit deletions, point mutations, or methylation inactivation in a variety of tumors. Methylation of the CpG island of CDKN2A was detected in 32/46 (70%) non-secreting adenomas, in contrast to 2/21 (9.5%) somatotroph adenomas and 0/15 histologically normal postmortem pituitaries (130). Methylation of CDKN2A corresponds to a loss of p16 expression on immunohistochemical analysis (130). When p16 is silenced, retinoblastoma protein (encoded by RB1) becomes phosphorylated, which enables cell cycle progression via the activation of E2F transcription factors (80). These observations indicate that the CDKN2A-related pathway is a potential target for non-secreting adenoma cell proliferation.

**Maternally Expressed 3**

MEG3 is a maternally expressed imprinted lncRNA that is transcribed from multiple transcriptional variants with different splicing patterns, all of which are lncRNAs. Several
studies have shown that MEG3-encoded lncRNA is a tumor suppressor that interacts with p53 and regulates expression of the p53 gene (TP53) (79, 131). In NF-PAs, MEG3 was found to be hypermethylated in both the 5’ region of the first exon and approximately 1.6–2.1 kb upstream of the first exon, leading to the silencing of gene expression (79). Hypermethylation in the regulated area of MEG3 is an important mechanism that likely leads to the loss of MEG3 expression in clinical NF-PAs.

Ectodermal-Neural Cortex 1
Methylated EN1 has been found in tumor samples, and decreased levels were detected compared with normal pituitary glands (132). Notably, EN1 expression levels are reportedly lower in invasive null cell adenomas than in non-invasive adenomas (133, 134).

Inhibitor of Growth Family Member 2
ING2 is a member of the growth inhibitor family, and participates in regulating the activity of histone acetyltransferase and histone deacetylase complexes, and plays a role in DNA repair and apoptosis. Methylation sequencing of NF-PAs revealed the presence of ING2 DNA methylation in NF-PAs, and the methylation and expression levels were correlated with tumor recurrence. Furthermore, clinical data have indicated that ING2 is an independent prognostic marker of NF-PAs (135).

Family with Sequence Similarity 90 Member A1
FAM90A1 is a primate-specific gene that is associated with ING2. FAM90A1 is also hypermethylated in NF-PAs, and the methylation level is significantly correlated with patient prognosis (135). FAM90A1 methylation likely plays a role in NF-PA tumorigenesis and is a potential marker of PA.

Common Methylations with Somatotroph Adenomas
Similar to somatotroph adenomas, NF-PAs also exhibit hypermethylation in the CpG island of the GADD45γ gene. In addition, the methylation of CDKN2A, MEG3, and RASSF1A has also been detected in NF-PAs. Most methylated genes are involved in the cell cycle and DNA damage repair. However, novel abnormally methylated genes, such as ING2 and FAM90A1, have also been detected, and their specific regulatory mechanisms remain unknown.

LACTOTROPH ADENOMAS
Lactotroph adenomas are the most common secretory tumors, accounting for 60% of all PAs. Microprolactinomas are usually stable and slow growing, and continued growth after diagnosis occurs in less than 15% of cases (2). Lactotroph adenomas are ideally managed with dopamine agonists (136). Dopamine agonists can reduce prolactin levels and shrink tumors; however, they have side effects, and 15% of patients are not sensitive to these drugs (2). Additional targets are therefore needed to improve lactotroph adenoma treatment. Here, we summarize the molecular variations that occur in lactotroph adenomas.

HMGA1 and HMGA2
HMGA proteins comprise a family of transcriptional regulating factors that are highly expressed during embryogenesis and play an important role in tumorigenesis in various tissues, including the pituitary gland. HMGA2 has been shown to be rearranged and amplified in lactotroph adenomas, and transgenic mice with Hmgα overexpression develop PAs with prolactin and GH secretion (137). The primary mechanism by which HMGA2 mutations lead to PAs involves an increase in E2F1 activity (138). It has also been reported that MIA is one of the most commonly downregulated genes in lactotroph adenomas, and this may serve as a downstream mechanism of HMGA2 (137, 139). The HMGA2 protein can bind to the DNA elements of pituitary-specific positive transcription factor 1 (PIT-1) and cause a PIT-1 reaction, thus positively regulating the production of the PIT-1 promoter. It is therefore speculated that HMGA2 leads to the proliferation of PIT-1-expressing cells or the abnormal proliferation of GH- and prolactin-secreting embryonic cells (137, 140). In addition, the downregulation of miRNAs may be related to the accumulation of HMGA2, which might lead to the proliferation of pituitary cells. In one study, the expression of miR-let-7 was reported to be decreased in 23 of 55 (42%) lactotroph adenomas, and was negatively correlated with the expression of HMGA2 (141). The overexpression of HMGA2 protein is also positively correlated with pituitary tumor phenotype, and overexpression of Hmgα in transgenic mice results in the development of PA (142). Therefore, HMGA2 is a specific oncogene for pituitary transformation. However, according to the current evidence that has been collected on genes in the HMGA family, only HMGA2 has a direct causal role in human pituitary tumorigenesis because it is amplified or rearranged in human lactotroph adenomas. It has been reported that HMGA1 and HMGA2 nuclear expression levels are significantly higher in invasive adenomas than in non-invasive adenomas (143, 144).

Prolactin Receptor
The deletion of the PRLR-encoding gene leads to aggressive pituitary tumors in mice, while homozygous deletion mutants of PRLR in patients with hyperprolactinemia and agalactia do not lead to pituitary tumors (145). In contrast, a gain-of-function mutation was found in 9 of 46 patients with lactotroph adenomas, representing a potential novel mechanism for lactotroph adenoma tumorigenesis. In addition, three other rare variants and two low-frequency variants found in this cohort may represent benign changes (146). However, further investigations are needed to confirm the underlying mechanisms.

THYROTROPH ADENOMAS
Thyrotroph adenomas are the least common type of PAs, accounting for approximately 1% of all adenomas. Thyrotroph adenomas lead to elevated or inappropriately suppressed thyrotropin levels, with normal or elevated thyroid hormone levels. Sapkota et al. confirmed six DNA variants as candidate driver mutations; two of these mutations were identified in genes
with an established role in malignant tumorigenesis (SMOX and SYTL3), while four had unknown roles (ZSCAN23, ASTN2, R3HDM2, and CWH43) (147). Similarly, a single nucleotide polymorphism array analysis revealed frequent chromosomal regions of copy number gains, including recurrent gains at the loci harboring these six genes. In addition, Ando et al. reported a somatic mutation in the ligand-binding domain of thyroid hormone receptor beta (TRbeta) that causes a His to Tyr substitution at codon 435 of TRbeta1, corresponding to codon 450 of TRbeta2 (148). Unlike other PAs, thyrotroph adenomas are rarely associated with genetic syndromes or common somatic mutations.

ALL TYPES

Gain or loss of chromosome. A non-random gain in pituitary tumors has been reported in chromosomes 5, 8, 12, and X (149, 150). Gains of chromosomes 8 and 12 were found in prolactinomas and non-secreting adenomas, whereas a combined loss of chromosomes 5 and 8 was observed in corticotroph and somatotroph adenomas. In addition, recurrent structural rearrangements affecting chromosomes 1, 3, and 12 have also been identified in prolactinomas, which appear to be the only PA subtype with a defined trend of tumor-specific chromosomal changes (149). In another whole-exome sequencing investigation, 75% of the highly disrupted group were functional adenomas or atypical null cell adenomas, whereas 87% of the less-disrupted group were non-functional adenomas (151). The disrupted samples were characterized by expression changes associated with poor outcomes in other cancers. Furthermore, arm-level losses of chromosomes 1, 2, 11, and 18 were significantly recurrent (151). These data indicate that sporadic PAs have distinct copy-number profiles that are associated with hormonal and histological subtypes and influence gene expression.

Transcription factors. Cell lineages of the pituitary are dependent on the expression of the pituitary transcription factors PIT1, TPT1, and SF1 that, in concert with ERTα and GATA2/3, regulate cellular differentiation and hormone secretion (152). Recently, these transcription factors (PIT1 for GH, prolactin, and TSH lineages; SF1 for gonadotroph lineages; and TPT1 for ACTH lineages) have been added to the classification (152, 153).

DNA methylation. Frequently methylated genes (i.e., CDKN2A, GADD45y, FGFR2, CASP8, and PTAG) demonstrate methylation in over 50% of PAs; moderately methylated genes (i.e., TSP-1, RASSF1A, RB1, p73, MGMT, and CDH1) demonstrate methylation in 20–50% of PAs; and infrequently methylated genes (i.e., p14, DAPK1, TIMP3, p21, and p27) are methylated in less than 20% of PAs (79, 154). These variable rates of methylation may reflect a variety of factors.

Implications for therapy. In a subset of pituitary tumors that are refractory to routine therapy, both MGMT promoter hypermethylation in aggressive PAs and pituitary carcinomas and low protein expression have been implicated. Hypermethylation of MGMT indicates a better response to treatment with temozolomide (TMZ) in some aggressive PAs (155). In one study, combination treatment with TMZ and pyrimethamine (PYR) produced synergistic antitumor activity both in vivo and in vitro. Moreover, TMZ/PYR treatment induced cell cycle arrest, increased DNA damage, and upregulated the expression of caspethin B, BAX, cleaved PARP, and phosphorylated histone H2AX; it also elevated caspase 3/7, 8, and 9 activities. Therefore, PYR may enhance the efficacy of TMZ by triggering both caspethin B- and caspase-dependent apoptotic pathways. A combination of PYR and TMZ may thus provide a novel regimen for invasive PAs that are refractory to standard therapy and TMZ alone (156).

CONCLUSION

We reviewed older and more recent discoveries of molecular variations in somatotroph adenomas, corticotroph adenomas, lactotroph adenomas, non-secreting adenomas, and thyrotroph adenomas. Summarizing the genetic and epigenetic markers of different types of PAs and elucidating their comprehensive molecular mechanisms will be helpful to identify the physiological pathways of PAs. These findings will provide a better understanding of the occurrence of PAs and lead to the development of novel therapeutic treatments.

AUTHOR CONTRIBUTIONS

CM wrote the manuscript of this paper, and YC helped in modifying the manuscript. BX and WR directed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Key R&D Program of China (2018YFA0108602, 2018YFA0108600 to XB), China Postdoctoral Science Foundation (BX20190045 to MC), Beijing Municipal Natural Science Foundation (7182134 to XB), CAMS Initiative for Innovative Medicine (CAMSII2M) (2016-I2M-1-017 to XB), CAMS Young Talents Award Project (2018RC320003 to XB), and Beijing Nova Program (Z18110006218003 to XB).

REFERENCES

1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol (2014) 16 Suppl 4(Suppl 4):iv–163. doi: 10.1093/neuonc/nou223
2. Melmed S. Pituitary-Tumor Endocrinopathies. N Engl J Med (2020) 382 (10):937–50. doi: 10.1056/NEJMra1810772
3. Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, et al. The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing’s Disease and Endocrine-Inactive Subtypes. Clin Cancer Res (2018) 24(17):4126–36. doi: 10.1158/1078-0432.ccr-17-2206
4. Tian Y, Yang J, Li B, Li Y, Liu X. FGF20 promotes tumorigenesis in pituitary adenomas through PI3K/AKT signaling. FEBS Lett (2018) 592(16):2772–9. doi: 10.1002/ls.20297
4. Reddy R, Cudlip S, Byrne JV, Karavitaki N, Wass JA. Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functional pituitary adenoma? Eur J Endocrinol (2011) 165(5):739–44. doi: 10.1530/eje-11-0566

5. Caimari F, Korbonits M. Novel Genetic Causes of Pituitary Adenomas. Clin Cancer Res (2016) 22(20):5030–42. doi: 10.1158/1078-0432.Ccr-16-0452

6. Maxwell JE, Sherman SK, Howe JR. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clin Cancer Res (2016) 22(20):5022–9. doi: 10.1158/1078-0432.Ccr-16-0435

7. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab (2010) 24(3):355–70. doi: 10.1016/j.bpcem.2010.07.003

8. Longuini VC, Lourencó JM, Sá-Pinto S, de Oliveira CG. Diagnosis of mosaic mutations in the MEN1 gene by next generation sequencing. Eur J Endocrinol (2019) 180(2):L1–L3. doi: 10.1530/eje-18-0852

9. Balogh K, Patôcs A, Hunyady L, Rácz K. Menin dynamics and functional insight: take your partners. Mol Cell Endocrinol (2010) 326(1-2):80–4. doi: 10.1016/j.mce.2010.04.011

10. Beijers H, Stikkelbroeck NML, Mensenkamp AR, Pflünder R, van der Luijt RB, Timmers H, et al. Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 (MEN1) syndrome. Eur J Endocrinol (2019) 180(2):K15–K19. doi: 10.1530/eje-18-0778

11. Cappiello L, Ferriére A, Crepín M, Haissaguerre M, Ladsous M, Tabarin A, et al. Diagnosis of mosaic mutations in the MEN1 gene by next generation sequencing. Eur J Endocrinol (2019) 180(2):L1–L3. doi: 10.1530/eje-18-0852

12. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab (2009) 94(5):1826–34. doi: 10.1210/jc.2009-0208-2083

13. Kyritsi EM, Hasiotou M, Kanaka-Gantenbein C. Partial empty sella syndrome. Eur J Endocrinol (2014) 170(3):T105. doi: 10.1530/eje-14-0130

14. Hozumi K, Fukuoka H, Odake Y, Takeuchi T, Uehara T, Sato T, et al. Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. Endocr J (2019) 66(10):853–7. doi: 10.1507/endocrj.Ej19-0035

15. Lonser RR, Butman JA, Kiringoda R, Song D, Old AJ, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab (2015) 100(5):E710–9. doi: 10.1210/jc.2014-4297

16. O’Toole SM, Dénès J, Robledo M, Stratakis CA, Korbonits M. 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and pheochromocytomas or paragangliomas. Endocr Relat Cancer (2015) 22(4):T105–22. doi: 10.1530/erc-15-0241

17. Dénès J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab (2015) 100(3):E531–41. doi: 10.1210/jc.2014-3399

18. Xekouki P, Pacak K, Almeida M, Wassif CA, Rustin P, Nesterova M, et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDHFs. J Clin Endocrinol Metab (2012) 97(3):E357–66. doi: 10.1210/jc.2011-1179

19. Xekouki P, Stratakis CA. Succinate dehydrogenase (SDH) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer (2012) 19(6):C33–40. doi: 10.1530/erc-12-0118

20. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function, and decay. Nat Rev Genet (2010) 11(9):597–609. doi: 10.1038/nrg2821

21. de Kock L, Plourde F, Csako G, Rey R, Stratakis CA, Korbonits M. Germline or somatic GPR101 duplication leads to X-linked acromegaly. Acta Neuropathol Commun (2015) 3:doi: 10.1186/s40478-016-0326-1

22. Jacono AA, Mattern J, Moschos SJ, Horvath S, Healy M, et al. Peptide-producing tumors: the role of somatic mutations in neuroendocrine cancer. Best Pract Res Clin Endocrinol Metab (2015) 29(1):29–51. doi: 10.1016/j.bpcem.2014.09.002

23. Iacovazzo D, Caswell R, Bunce B, Jose S, Yuan B, Hernández-Ramírez LC, et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinicopathological and genetic study. Acta Neuropathol Commun (2016) 4(1):56. doi: 10.1186/s40478-016-0326-1

24. Gill AJ, Toon CW, Clarkson A, Sioson L, Chou A, Winship I, et al. Succinate dehydrogenase deficiency is rare in pituitary adenomas. Am J Surg Pathol (2013) 38(4):560–6. doi: 10.1097/psa.000000000000149

25. Xekouki P, Saeed B, Boulva P, Guibellino A, Quezado M, Mastroyannis SA, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase gene defects in humans and mice. J Clin Endocrinol Metab (2015) 100(5):E710–9. doi: 10.1210/jc.2014-4297

26. Neou M, Villa C, Armingnocca R, Jouinot A, Tichomirowa MA, Petrossians P, et al. Pheochromocytoma, paraganglioma, and acromegaly: two independent genetic syndromes. Endocr Relat Cancer (2016) 23(2):235–43. doi: 10.1530/erc-15-0241

27. Dénès J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab (2015) 100(3):E531–41. doi: 10.1210/jc.2014-3399

28. Xekouki P, Pacak K, Almeida M, Wassif CA, Rustin P, Nesterova M, et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDHFs. J Clin Endocrinol Metab (2012) 97(3):E357–66. doi: 10.1210/jc.2011-1179
systematic review of the literature. PLoS One (2013) 8(12):e82619. doi: 10.1371/journal.pone.0082619
80. Zhu X, Lee K, Aza SL, Erazt S. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol (2007) 170(5):1618–28. doi: 10.2353/ajpath.2007.061111
81. Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE. Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation. Oncogene (2004) 23(4):396–44. doi: 10.1038/sj.onc.1207193
82. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab (2002) 87(1):1262–7. doi: 10.1210/jc.87.3.3851
83. Rejnick M, Shiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet (2015) 47(1):31–8. doi: 10.1038/ng.3166
84. Jian FF, Li YF, Chen YF, Jiang H, Chen X, Zheng LL, et al. Inhibition of ubiquitin-specific Peptidase 8 Suppresses Adrenocorticotropic Hormone Production and Tumorous Corticotroph Cell Growth in AtT20 Cells. Clin Med J (Engl) (2016) 129(17):2102–8. doi: 10.4103/0366-6999.189047
85. Weigand I, Knobloch L, Flitsch J, Saeger W, Monzonu CU, Höfner K, et al. Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. J Clin Endocrinol Metab (2019) 104(7):2535–46. doi: 10.1210/jc.2018-02564
86. Bujko M, Kober P, Boreszowicz J, Rusetzka N, Paziewska A, Dąbrowska M, et al. USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status. Eur J Endocrinol (2019) 181(6):615–27. doi: 10.1530/eje-19-0194
87. Cohen M, Persky R, Stegemann R, Hernández-Ramírez LC, Zeltser D, Lodish MB, et al. Germline USP8 Mutation Associated With Pediatric Cushing Disease and Other Clinical Features: A New Syndrome. J Clin Endocrinol Metab (2019) 104(10):4676–82. doi: 10.1210/jc.2019-00999
88. Albani A, Perez-Rivas LG, Dimopoulos C, Zepp S, Colón-Bola P, Roebber S, et al. The USP4 mutational status may predict long-term remission in patients with Cushing’s disease. Clin Endocrinol (Oxf) (2018) 89(4):454–8. doi: 10.1111/cen.13802
89. Faucz FR, Tirosch A, Tarsi C, Berthon A, Hernández-Ramírez LC, Settas N, et al. Somatic USP4 Gene Mutations Are a Common Cause of Pediatric Cushing Disease. J Clin Endocrinol Metab (2017) 102(8):2836–43. doi: 10.1210/jc.2017-00161
90. Waniichi IQ, de Paula Mariani BM, Frassetto FP, Siqueira SAC, de Castro Musolino NR, Cunha-Neto MBC, et al. Cushing’s disease due to somatic USP4 mutations: a systematic review and meta-analysis. PLoS Pathog (2019) 22(4):435–42. doi: 10.1101/2019.01.00739-9
91. Asari Y, Kageyama K, Sugiyama A, Kogawa H, Nioka K, Daimon M, Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. Endocr J (2019) 66(6):515–22. doi: 10.1507/endocrjJE18-0491
92. Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisamita A, Suzuki H, Fukuhara N, et al. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing’s disease. J Clin Endocrinol Metab (2016) 104(3):213–26. doi: 10.1210/jc.2015-0079-9
93. Bruns C, Lewis I, Briner U, Meno-Tetag G, Weckbecker G. SOM230: a novel somatostatin pentapeptide with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antiserotonin profile. Eur J Endocrinol (2002) 146(5):707–16. doi: 10.1530/joe.0.1460707
94. Chen J, Jian X, Deng S, Ma Z, Shou X, Shen Y, et al. Identification of recurrent USP4 and BRAF mutations in Cushing’s disease. Nat Commun (2018) 9(1):3171. doi: 10.1038/s41467-018-05275-5
95. Shiera S, Perez-Rivas LG, Tarantos L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in USP4 wild-type Cushing’s disease. Neuron Oncol (2021) 20(10):1273–83. doi: 10.1093/neuonc/noz109
96. Riebold M, Kozany C, Freiherger L, Sattler M, Buchfelder M, Haasch F, et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med (2015) 21(3):276–80. doi: 10.1038/nm.3776
97. Błodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary Tumor Suppressor Cell Line. Horm Metab Res (2019) 51(7):550–7. doi: 10.1055/s-0043-1026437
98. Ragnarsson O, Olsson DS, Chantichristos D, Papakokkinou E, Dahlvist P, Segerstedt E, et al. The incidence of Cushing’s disease: a nationwide Swedish study. Pituity (2019) 22(2):179–86. doi: 10.1016/j.s11481-019-00951-1
99. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MJ, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice GuideLine. J Clin Endocrinol Metab (2015) 100(8):2807–31. doi: 10.1210/jc.2015-1818
100. Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hollden IJ, Lacroix A. Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol (2017) 5(4):300–12. doi: 10.1016/S2213-8587(18)30155-4
101. Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, Zhou LF, et al. Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res (2015) 25(3):306–17. doi: 10.1038/cr.2015.20
102. Perez-Rivas LG, Theodoropoulou M, Ferraiu F, Nusser C, Kawaguchi K, Stratakis CA, et al. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing’s Disease. J Clin Endocrinol Metab (2015) 100(7):E997–1004. doi: 10.1210/jc.2015-1453
103. Reinecke M, Shiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet (2015) 47(1):31–8. doi: 10.1038/ng.3166
104. Jian FF, Li YF, Chen YF, Jiang H, Chen X, Zheng LL, et al. Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Adrenocorticotropic Hormone
117. Zheng W, Nowakowski RS, Vaccarino FM. Fibroblast growth factor 2 is required for maintaining the neural stem cell pool in the mouse brain subventricular zone. Dev Neurosci (2004) 26(4):281–96. doi: 10.1159/000070314

118. Farrell WE. A novel apoptosis gene identified in the pituitary gland. Neuroendocrinology (2006) 84(4):217–21. doi: 10.1159/000097846

119. Ren J, Gu C, Yang Y, Xue J, Sun Y, Jian F, et al. TSP-1 is downregulated and inversely correlates with mdr-44k expression in Cushing’s disease. J Cell Mol Med (2019) 23(6):4097–110. doi: 10.1111/jcmm.14297

120. Renjie W, Haigian L. MIR-132, MIR-15a and MIR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer Lett (2015) 356(2 Pt B):568–78. doi: 10.1016/j.canlet.2014.10.003

121. Gentilin E, Tagliati F, Filieri C, Molé D, Minoia M, Rosaria Ambrosio M, et al. MIR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cb. Endocrinology (2011) 154(5):1690–700. doi: 10.1210/en.2011-2070

122. Gentilin E, Di Pasquale G, Caggiano T, Tagliati F, Benfiniti K, Ambrosio MR, et al. Protein Kinase Cb Delta restrains growth in ACTH-secreting pituitary adenoma cells. Mol Cell Endocrinol (2016) 419:252–8. doi: 10.1016/j.mce.2015.10.025

123. Yu G, Li C, Xie W, Wang Z, Gao H, Cao L, et al. Long non-coding RNA C5orf66-A51 is downregulated in pituitary null cell adenomas and is associated with their invasiveness. Oncol Rep (2017) 38(2):1140–8. doi: 10.3892/or.2017.5739

124. Sleiter N, Pang Y, Park C, Horton TH, Dong J, Thomas P, et al. Progesterone receptor A (PRA) and PRB-independent effects of progesterone on adenoma cells. Mol Med (2016) 22(7):3833–44. doi: 10.1016/j.molmed.2016.08.0774

125. Feng J, Yu SY, Li CZ, Li ZY, Zhang YZ. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas. Mol Cell Endocrinol (2016) 436:195–203. doi: 10.1016/j.mce.2016.07.025

126. Martinez-Lopez S, Garcia-Martinez A, Torregrosa-Quesada M, Lopez-Muñoz B, Cámara R, Fajardo C, et al. Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors? J Endocrinol Invest (2020) 43(8):859–63. doi: 10.1007/s40618-019-01166-8

127. Karakas B, Bachman KE, Park BH. Mutation of the PTK3CA oncogene in human cancers. Br J Cancer (2006) 94(4):455–9. doi: 10.1038/sj.bjc.6602970

128. Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M, et al. Frequent mutations and Frontiers in Endocrinology | www.frontiersin.org January 2021 | Volume 11 | Article 59655416

129. Chang et al. Pituitary Tumorgenesis Mechanism

130. Sleiter N, Pang Y, Park C, Horton TH, Dong J, Thomas P, et al. Progesterone receptor A (PRA) and PRB-independent effects of progesterone on adenoma cells. Mol Med (2016) 22(7):3833–44. doi: 10.1016/j.molmed.2016.08.0774

131. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, et al. Activation of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res (1994) 54(21):5695–701.

132. Palmeri D, Valentino T, De Martino I, Esposito F, Cappabianca P, Wierinckx A, et al. PTIP upregulation by HMGA1 proteins has a role in pituitary tumorigenesis. Endocr Relat Cancer (2012) 19(2):123–35. doi: 10.1530/erc-11-0135

133. Qian ZR, Asa SL, Haimouk D, Yamauchi T, Sun Y, Jian F, et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol (2009) 22(3):431–41. doi: 10.1038/modpathol.2008.202

134. Holm R. Null cell adenomas and oncocytomas of the pituitary gland. J Clin Endocrinol Metab (2006) 91(6):2227–33. doi: 10.1210/jc.2005-0384

135. Cheng S, Li C, Xie W, Miao Y, Guo J, Wang J, et al. Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma. Aging (Albany NY) (2020) 12(3):2408–27. doi: 10.18632/aging.102751

136. Melmed S, Casparie FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 96(2):273–88. doi: 10.1207/s15300373jecm10622-10
and caspase-dependent apoptotic pathways. *Int J Cancer* (2013) 133 (8):1982–93. doi: 10.1002/ijc.28199

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.